Sunday, 16 August 2026European Markets
ExploreSearch
ViaNews EU
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Move to Shore Up Trust as Leadership Shifts and AI-Adjacent Markets Wobble
Major AI and media platforms are converging on trust and accountability measures — Anthropic's Claude adding watermarks, Spotify labeling AI artists — just as OpenAI loses special-projects lead Brad Lightcap and Meta's Zuckerberg publishes a defensive manifesto on AI's societal role. In parallel, AI-adjacent financial dynamics are surfacing real stress: Wall Street firms are paying for privileged early access to Trump's Truth Social posts for trading edge, while Trump Media itself reports a $238M loss driven by falling crypto holdings, highlighting how information asymmetry and speculative digital assets are becoming entangled with AI-era platforms.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,809
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,809 facts checked against source5,205 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 12, 2026

Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight

View original at globenewswire.com
Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight New York, USA, Jan…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • In 2024, the total diagnosed prevalent cases of ASCVD across the 7MM were approximately 65 million, and this burden is projected to rise over the forecast period

    80% confidence

  • The atherosclerotic cardiovascular disease market in the 7MM is expected to show positive growth during the forecast period (2025-2034) at a CAGR of 4.9%

    80% confidence

  • In the United States, systemic inflammation-associated ASCVD cases were estimated at approximately 17 million in 2024

    80% confidence

  • The ASCVD clinical trial landscape is undergoing a notable transition, moving beyond traditional LDL-C-focused strategies toward more targeted, mechanism-based interventions for cardiovascular risk reduction

    80% confidence

  • The market size for atherosclerotic cardiovascular disease was USD 23 billion in the leading markets in 2024

    80% confidence

  • The dynamics of the ASCVD market are expected to change in the coming years due to the launch of emerging therapies

    80% confidence

  • The United States accounted for approximately 75% of the total ASCVD market size in the 7MM in 2024

    80% confidence

  • While marketed therapies have cemented PCSK9 inhibition as a powerful intervention, uptake challenges have left room for innovation. This gap is now fueling a new wave of competition with oral, long-acting, and gene-editing approaches.

    80% confidence

  • Despite strong clinical validation, real-world adoption challenges for existing PCSK9 inhibitors have opened the door to next-generation therapies

    80% confidence

  • The advancement of late-stage candidates such as Amgen's olpasiran and Ionis/Novartis' pelacarsen highlights the increasing clinical and commercial emphasis on lipoprotein(a), a genetically determined and long-overlooked contributor to residual ASCVD risk

    80% confidence
Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight — Source | Via News | ViaNews EU